ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fibromyalgia"

  • Abstract Number: 1332 • ACR Convergence 2025

    Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases

    Gilad Halpert1, Yair Dankner2, Eri Govrin1, Abdulla Watad3, Omer Gendelman1, Shlomo Segev1, Yehuda Shoenfeld1 and Howard Amital1, 1Sheba Medical Center, Ramat Gan, Israel, 2Shenkar College of Engineering and Design, Ramar Gan, Israel, 3Tel Hashomer Medical Center, Ramat Gan, Israel

    Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…
  • Abstract Number: 0814 • ACR Convergence 2025

    Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes

    Annie Brink1, Johan Karlsson Wallman2, Jon T Einarsson1, Meliha Kapetanovic1, Elisabeth Mogard1, Elisabet Lindqvist1, Carmen Roseman1, Kristina Lend3, Merete Hetland4, Mikkel Ostergaard5, Kim Horslev-Petersen6, Dan Nordstrom7, Tuulikki Sokka-isler8, Bjorn Gudbjornsson9, Gerður María Gröndal9, Marte Heiberg10, Espen Haavardsholm10, Michael Nurmohamed11, Anna Rudin12, Ronald van Vollenhoven13, Till Uhlig10, Jon Lampa14 and Tor Olofsson2, 1Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, 2Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, 3Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam; Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 4Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, 5Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, 6Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, 7Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, 8Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Juväskylä, Finland, 9Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 10Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 11Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, 12Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 13Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, 14Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Emerging data indicate an uncoupling between pain and inflammation during the RA disease course, and comorbid fibromyalgia – thought to stem from central pain…
  • Abstract Number: 1254 • ACR Convergence 2025

    Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey

    Lesley Arnold1, Zhao Yang2, Parul Houston2, Todd Grinnell2 and Daniel Clauw3, 1University of Cincinnati College of Medicine, Cincinnati, OH, 2Axsome Therapeutics, Inc, New York, NY, 3Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI

    Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder driven by dysregulated central pain processing which substantially impairs daily function and quality of life. Approved…
  • Abstract Number: 0534 • ACR Convergence 2025

    Prevalence and Impact of Fibromyalgia on Disease Outcomes and Treatment in Axial Spondyloarthritis: 10-year Follow-up Data From the DESIR Cohort

    Clementina López Medina1, Sylvie Chevret2, Cedric Lukas3, Anna Molto4 and Maxime Dougados2, 1Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, 2Université Paris-Cité, Paris, France, 3CHU Montpellier, Montpellier, France, 4Assistance Publique Hôpitauxde Paris, Paris, France

    Background/Purpose: Concomitant fibromyalgia (FM) can be suspected in patients (pts) with axial SpA (axSpA) using the Fibromyalgia Rapid Screening Tool (FiRST).The objective of this study…
  • Abstract Number: 1245 • ACR Convergence 2025

    Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)

    Rubab Rizwan, Sehneet Grewal, Sri Varsha Banda and Mohammad Hazique, Nuvance Health, poughkeepsie, NY

    Background/Purpose: Fibromyalgia is a chronic condition marked by widespread pain that can significantly reduce a patient’s quality of life. While low-dose naltrexone (LDN) has emerged…
  • Abstract Number: 0225 • ACR Convergence 2025

    Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses

    Juan Schmukler1, Tengfei Li2 and Theodore Pincus1, 1Rush University Medical Center, Chicago, IL, 2Rush, chicago, IL

    Background/Purpose: Comorbid anxiety (ANX), depression (DEP), and fibromyalgia(FM) are reported as more common in patients with rheumatoid arthritis (RA) and other rheumatic diagnoses than in…
  • Abstract Number: 1244 • ACR Convergence 2025

    PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems

    Rosemary Hollick1, Marcus Beasley1, Ernest Choy2, Caroline Cupit3, Debra Dulake1, Teresa Finlay3, Louise Locock1, Paul McNamee1, Catherine Pope3, Elaine Wainwright1, David Williams4 and Gary Macfarlane1, 1University of Aberdeen, Aberdeen, United Kingdom, 2Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, 3University of Oxford, Oxford, United Kingdom, 4University of Michigan, Michigan

    Background/Purpose: Fibromyalgia is a contested and poorly supported condition, characterised by widespread pain, fatigue, and cognitive symptoms, often compounded by stigma and delayed diagnosis. Existing…
  • Abstract Number: 0197 • ACR Convergence 2025

    Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA

    Theodore Pincus1, Juan Schmukler1 and Tengfei Li2, 1Rush University Medical Center, Chicago, IL, 2Rush, chicago, IL

    Background/Purpose: A symptom checklist and screening indices for anxiety (ANX), depression (DEP), and/or fibromyalgia (FM) on patient questionnaires such as a multidimensional health assessment questionnaire…
  • Abstract Number: 1242 • ACR Convergence 2025

    Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants

    Robert Katz1, Alexandra Katz Small2, Edwin Moore3 and Seth Adler4, 1Rush University Medical Center, Chicago, IL, 2Rheumatology Associates, CHICAGO, IL, 3University of Illinois Urbana Champaign, CHICAGO, IL, 4Rush University Medical Center, Chicago, IL

    Background/Purpose: Fibromyalgia (FM) is a multifaceted disorder defined by chronic widespread pain, sleep disruption, fatigue, and cognitive difficulties. Although the predominant theory behind FM pathogenesis…
  • Abstract Number: 1243 • ACR Convergence 2025

    Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study

    Robert Katz1 and Alexandra Katz Small2, 1Rush University Medical Center, Chicago, IL, 2Rheumatology Associates, CHICAGO, IL

    Background/Purpose: Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, cognitive disturbances, and poor sleep. Despite accumulating evidence of immune involvement, a…
  • Abstract Number: 1237 • ACR Convergence 2025

    Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management

    Michael Rosenbluth1, Yifei Dai1, Dianne Shumay1 and Andrea Chadwick2, 1Swing Therapeutics, San Francisco, CA, 2University of Kansas School of Medicine, Kansas City, KS

    Background/Purpose: Guidelines for fibromyalgia treatment recommend non-pharmacologic treatment, including cognitive behavioral therapy, alongside medications [1-3]. However, patient access to multi-modal treatment is frequently limited due…
  • Abstract Number: 1178 • ACR Convergence 2024

    Can Immersive Virtual Reality Improve the Effect of Meditation for People with Fibromyalgia?

    Nancy Baker1, Aliza Spielman1 and Robert Edwards2, 1Tufts University, Medford, 2Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Fibromyalgia (FM) is a common and disabling condition characterized by widespread muscular pain. Meditation has been shown to alleviate affective pain in people with…
  • Abstract Number: 2163 • ACR Convergence 2024

    Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App

    Marc Blanchard1, Cinja Koller2, Patrick Hermann1, Johanna Mettler1, Tiffany Prétat3, Pedro Ming Azevedo3 and Thomas Hügle3, 1Lausanne University Hospital, Lausanne, Vaud, Switzerland, 2Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, 3Lausanne University Hospital, Lausanne, Switzerland

    Background/Purpose: Mobile health apps have demonstrated effectiveness in managing chronic musculoskeletal pain syndromes such as fibromyalgia. We developed an app called POCOS for chronic musculoskeletal…
  • Abstract Number: 1212 • ACR Convergence 2024

    Childhood Maltreatment Increases Risk of Chronic Widespread Pain: Counterfactual Analysis of UK Biobank

    Kate Timmins1, Tim Hales2 and Gary Macfarlane1, and The Consortium Against Pain inEquality Investigators and Advisory Group, 1University of Aberdeen, Aberdeen, United Kingdom, 2University of Dundee, Dundee, United Kingdom

    Background/Purpose: Adverse childhood experiences (ACEs), including maltreatment (abuse and neglect), have been associated with chronic pain, but the evidence is largely cross-sectional. Existing evidence is…
  • Abstract Number: 2173 • ACR Convergence 2024

    Hope and Health in Adolescents with Chronic Musculoskeletal Pain

    Irene Chern1, Mackenzie McGill2, Nellie P Butler2 and Sabrina Gmuca2, 1St. Christopher's Hospital for Children, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Hope, the capability to derive pathways to desired goals and motivate oneself via agency thinking plays a protective role in pediatric health contributing to…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology